Arcturus Therapeutics Holdings Inc.
Nasdaq · CIK 0001768224 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$2.1M
Operating Income
$-28.9M
Net Income
$-27.0M
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $2.1M | - | - |
| Operating Income | $-28.9M | - | - |
| Net Income | $-27.0M | - | - |
| Eps Basic | -0.95 | - | - |
| Eps Diluted | -0.95 | - | - |
| Cash And Equivalents | $211.4M | - | - |
| Total Assets | $245.4M | - | - |
| Total Liabilities | $54.0M | - | - |
| Shareholders Equity | $191.4M | - | - |
| Operating Cash Flow | $-19.4M | - | - |
| Capital Expenditures | $0 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Arcturus Therapeutics Holdings Inc. | 2026-05-07 | 0001193125-26-211943 |
| 10-K | Arcturus Therapeutics Holdings Inc. | 2026-03-03 | 0001193125-26-088391 |
| 10-Q | Arcturus Therapeutics Holdings Inc. | 2025-11-12 | 0001193125-25-275758 |
| 4 | Arcturus Therapeutics Holdings Inc. | 2025-08-19 | 0001193805-25-001212 |
| 10-Q | Arcturus Therapeutics Holdings Inc. | 2025-08-11 | 0000950170-25-106560 |